HR 5725, the Mental Health Crisis Response Act of 2025, establishes a federal grant program to help state and local governments create health-centered alternatives for mental health emergencies. It provides $25 million annually (2027-2031) for jurisdictions to embed mental health professionals in 911 systems, develop direct routing to crisis hotlines like 988, and build partnerships between emergency services and dispatch centers. The bill specifically aims to reduce law enforcement involvement in behavioral health crises by creating streamlined pathways to crisis care, without requiring police removal or overriding state emergency authority laws. Jurisdictions receiving grants must report on response times, use of force, and diversion rates to health services.
SRES 560 is a non-binding Senate resolution recognizing that mercury pollution causes severe health risks, including brain damage, kidney issues, and birth defects. It cites mercury's sources (fossil fuel plants), notes 3,700+ active fish consumption advisories nationwide, and states that 80 million Americans live near power plants emitting mercury. The resolution specifically urges the EPA to maintain current mercury emission controls and emphasizes there is "no known safe level" of exposure. As a symbolic resolution, it does not create new laws or policies but formally states the Senate's position on mercury health impacts.
This non-binding Senate resolution (SRES 566) recognizes the critical role of Department of Veterans Affairs (VA) employees in providing essential health care to veterans. It highlights the VA's service to over 7 million patients, high veteran trust in VA care, and its performance in quality metrics compared to non-VA facilities. The resolution urges the VA to support its employees and reaffirms congressional commitment to ensuring veterans have access to high-quality, veteran-centered care through VA facilities or community providers. It does not create new policies or funding but serves as a symbolic acknowledgment of VA staff contributions.
The Public Safety Retirees Healthcare Protection Act of 2025 increases the tax exclusion for health and long-term care insurance premiums paid by retired public safety officers from $3,000 to $6,000 annually. This change applies to distributions from governmental retirement plans used for these insurance costs, directly affecting retired police officers, firefighters, and other public safety personnel. The bill amends the Internal Revenue Code to allow a higher portion of retirement income to remain tax-free for these retirees. It takes effect for taxable years beginning after December 31, 2025.
This bill allows seniors over 65 who only have Medicare Part A hospital insurance (and no other Medicare coverage) to contribute to Health Savings Accounts (HSAs). Currently, Medicare beneficiaries cannot contribute to HSAs, but this bill removes that restriction for seniors enrolled solely in Part A. The change amends the tax code to exclude these individuals from the existing HSA contribution ban during periods they have only Part A coverage. The provision takes effect for tax years beginning after December 31, 2024.
This bill requires Medicare Advantage (MA) plan advertisements to disclose specific data about prior authorization denials. Starting one year after enactment, ads must include the number of denied prior authorization requests, how many were later approved after reconsideration, and the average time between denial and approval. These disclosures must cover the most recent plan year before the ad is published, using both verbal and visual methods where possible. The policy directly affects MA plan marketers and beneficiaries who view these advertisements, aiming to provide clearer information about plan coverage experiences.
This bill requires the Congressional Budget Office (CBO) to identify potential budget savings from preventive health care in its scoring of proposed legislation. Specifically, it directs the CBO Director to describe and estimate reductions in future federal spending resulting from preventive health interventions - such as screenings or vaccinations - when requested by congressional budget committee leaders. These savings would be included as supplementary information in budget projections, but not used to meet budget enforcement rules. The bill does not change actual health programs or funding; it only modifies how the CBO accounts for potential long-term savings from preventive care in budget analysis.
This bill establishes a new process for the Department of Veterans Affairs (VA) to lease major medical facilities without requiring General Services Administration (GSA) approval. It creates a Veterans Leasing Fund to finance these leases and sets requirements for cost estimation, lease terms (maximum 20 years), and reporting to Congress. The bill mandates detailed cost estimates including construction, land, and material costs, with notifications to Congress if costs exceed approved estimates by more than 10%. It sets a one-year target for awarding leases and requires annual reports on procurement progress. The goal is to streamline the VA's process for building and leasing medical facilities for veterans.
HR 5385, the Health Providers Training Act, expands eligibility for existing health profession opportunity grants under the Social Security Act. It amends the law to include hospitals (as defined in Section 1861(e)) as eligible recipients alongside community-based organizations. This change allows hospitals to apply for federal grants aimed at training health professionals, directly affecting qualifying hospitals seeking funding for workforce development. The amendment takes effect on October 1, 2025.
HR 3375, the Fair Prescription Drug Prices for Americans Act, sets a cap on the U.S. list price for prescription drugs and biological products, limiting it to the average price charged in Canada, France, Germany, Italy, Japan, and the United Kingdom. Drug manufacturers must annually report U.S. and international list prices to the Health and Human Services Secretary, who calculates the average price for each drug. Manufacturers violating the price cap face civil penalties equal to 10 times the price difference per unit sold in the U.S. The bill directly affects drug manufacturers by restricting U.S. pricing and imposing financial penalties for noncompliance.
